Antibody Sugar Patterns in Spinal Fluid May Predict Recovery From NMDAR Encephalitis
Sugar-coating patterns on brain-fluid antibodies in NMDAR encephalitis differ by trigger and track with 1-year outcomes, hinting at a new prognostic biomarker.
Zusammenfassung
Researchers analyzed Fc-glycosylation, the sugar decoration on antibodies, in paired blood and spinal fluid (CSF) samples from 50 patients with anti-NMDAR encephalitis. Antibodies in CSF had less sialylation and galactosylation than those in serum, a more pro-inflammatory profile, suggesting localized immune activity in the central nervous system. This pattern was strongest in post-herpes cases, which also had more bisecting GlcNAc. Patients with poor one-year outcomes (mRS ≥3) had lower sialylation, galactosylation, and, in CSF, lower fucosylation at disease onset. The differences were modest and the cohort was small, with analyses that were exploratory and uncorrected for multiple testing. Even so, antibody glycan profiling could eventually serve as a prognostic biomarker, but validation in larger, independent cohorts is needed.
Detaillierte Zusammenfassung
Anti-NMDAR encephalitis is an autoimmune brain disorder that causes psychosis, memory problems, seizures, and reduced consciousness, mostly in young women. Most patients improve with immunotherapy, but a subset is left with lasting deficits, and no validated biomarker predicts who will recover. Antibody titers only partly explain the variation. This study asked whether qualitative antibody features, specifically the sugar groups (glycans) attached to the antibody Fc region, might add information.
The team studied 50 age- and sex-matched patients with NMDAR antibodies in both serum and CSF: 21 idiopathic, 19 tumor-related (mostly ovarian teratoma), and 10 post-herpes simplex encephalitis (post-HSE). Samples were taken at onset, a median of 15 days after symptoms began. Forty-one patients were immunotherapy-naive and nine had received steroids within the prior 1–3 months. IgG was purified and Fc glycans were measured by liquid chromatography–mass spectrometry for IgG1 and combined IgG2/3. Outcome at one year was classed as good (mRS ≤2) or poor (mRS ≥3); 27 patients had good outcomes and 23 poor.
CSF antibodies had significantly lower sialylation and galactosylation than paired serum antibodies across IgG subclasses (p < 0.0001), a profile linked to stronger inflammatory activity. IgG1 bisecting GlcNAc was also lower in CSF. A multivariate model separated CSF from serum with 84% cross-validated accuracy. Post-HSE patients showed the most inflammatory CSF profile compared with the other two groups, with lower sialylation and galactosylation and higher bisecting GlcNAc, which enhances NK-cell-mediated cytotoxicity. These differences were not seen in serum. This may reflect virus-induced immune activation, possibly through type I interferon signaling, which can alter glycosyltransferase expression in B cells.
Poor one-year outcome was associated with lower sialylation and galactosylation in both serum and CSF, and with lower IgG1 fucosylation in CSF. Afucosylated IgG binds FcγRIIIa on NK cells more strongly, which could promote antibody-dependent cytotoxicity. Disease severity and outcome rates did not differ by etiology, and the glycan-outcome associations persisted after excluding post-HSE cases, suggesting they are not merely a proxy for viral trigger.
The findings point toward Fc-glycan profiling as a possible prognostic tool, and toward innate immune mechanisms, beyond direct receptor internalization, in NMDAR encephalitis. Caveats are important. The cohort is small, especially for post-HSE (n=10), which prevented stratified outcome analyses. Nine patients received steroids before sampling. Univariate tests were exploratory and not corrected for multiple comparisons, and absolute glycan differences were modest. The study is retrospective, associations do not prove causation, and no independent validation cohort was used.
Wichtigste Erkenntnisse
- CSF antibodies showed markedly lower sialylation and galactosylation than serum across IgG1–3 subclasses (p < 0.0001), indicating a compartmentalized pro-inflammatory profile.
- A multivariate LASSO/PLSDA model distinguished CSF from serum antibody glycoprofiles with 84% cross-validated accuracy.
- Post-herpetic NMDAR encephalitis had the most inflammatory CSF IgG glycoprofile: less sialylation and galactosylation, more bisecting GlcNAc.
- Poor 1-year outcomes (mRS ≥3) were linked to lower sialylation and galactosylation in serum and CSF, plus lower CSF IgG1 fucosylation.
- Glycan-outcome associations persisted after excluding post-HSE cases, supporting potential prognostic value independent of viral trigger.
Methodik
Retrospective study of 50 age- and sex-matched NMDAR encephalitis patients (21 idiopathic, 19 tumor-related, 10 post-HSE) with paired onset serum and CSF samples. IgG Fc glycans on IgG1 and IgG2/3 were quantified by LC-MS and compared by compartment, etiology, and 1-year mRS outcome using univariate tests and LASSO/PLSDA multivariate modeling. Univariate glycan analyses were exploratory without multiple-testing correction.
Studienlimitierungen
The cohort was small, with only 10 post-HSE cases, which limited stratified analyses by age, sex, and etiology, and nine patients received steroids before sampling. Exploratory univariate tests were uncorrected for multiple comparisons, glycan differences were modest in absolute size, and there was no independent validation cohort. Mechanistic links to NK cell activity and interferon signaling are inferred rather than directly tested.
Hat dir diese Zusammenfassung gefallen?
Erhalte die neueste Longevity-Forschung jede Woche in deinen Posteingang.
E-Mail-Adresse zum Abonnieren eingeben: